SCHEMBL30726006

SCHEMBL30726006

C[Si](C)(C)CCOCn1cnc(-c2cccnc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PPARA Q07869 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.40
MAPT P10636 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
HTT P42858 2/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP2A6 P11509 3/20 0.40
ALDH1A1 P00352 4/20 0.39
TP53 P04637 3/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3508159 0.79 DGAT1 (0.40) HDAC1HDAC6SMN1; SMN2MAPTNPC1
SCHEMBL1785976 0.79 DGAT1 (0.39) HDAC1HDAC6SMN1; SMN2MAPTNPC1
SCHEMBL2608746 0.78 ALDH1A1 (0.40) PPARASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL12369723 0.77 HDAC1 (0.54) HDAC1HDAC6PPARASMN1; SMN2MAPT
SCHEMBL2121540 0.77 ALDH1A1 (0.40) SMN1; SMN2NPC1RAB9ACYP2C9CYP2C19
SCHEMBL10276944 0.77 S1PR1 (0.42) HDAC1HDAC6MAPTDGAT1S1PR1
SCHEMBL31074681 0.76 ALDH1A1 (0.40) SMN1; SMN2NPC1RAB9ACYP2C9CYP2C19
SCHEMBL2608752 0.76 ALDH1A1 (0.40) SMN1; SMN2NPC1RAB9ACYP2C9CYP2C19
SCHEMBL30722053 0.76 DGAT1 (0.41) HDAC1HDAC6DGAT1S1PR1
SCHEMBL10276518 0.76 DGAT1 (0.41) HDAC1HDAC6DGAT1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists MERCK SHARP & DOHME LLC (US) 2026-02-17 US disclosed
US-20240002359-A1 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists HCRTR2, HCRTR1, NPY1R HDAC1 582/4885HDAC6 742/4885PPARA 671/4885
US-20240002359-A1 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS HCRTR2, HCRTR1, OXTR HDAC1 763/4885HDAC6 678/4885PPARA 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.